MA31753B1 - Detection amelioree de l'expression de mage-a - Google Patents
Detection amelioree de l'expression de mage-aInfo
- Publication number
- MA31753B1 MA31753B1 MA32736A MA32736A MA31753B1 MA 31753 B1 MA31753 B1 MA 31753B1 MA 32736 A MA32736 A MA 32736A MA 32736 A MA32736 A MA 32736A MA 31753 B1 MA31753 B1 MA 31753B1
- Authority
- MA
- Morocco
- Prior art keywords
- mage
- gene
- primer
- expression
- methylation
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 230000011987 methylation Effects 0.000 abstract 2
- 238000007069 methylation reaction Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007855 methylation-specific PCR Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/30—Oligonucleotides characterised by their secondary structure
- C12Q2525/301—Hairpin oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2561/00—Nucleic acid detection characterised by assay method
- C12Q2561/113—Real time assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/10—Detection mode being characterised by the assay principle
- C12Q2565/101—Interaction between at least two labels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Abstract
L'INVENTION CONCERNE UN OLIGONUCLÉOTIDE, UNE AMORCE OU UNE SONDE COMPRENANT LA SÉQUENCE NUCLÉOTIDIQUE D'UNE QUELCONQUE SEQ ID NO. 5, 6, 7, 2, 3, 4, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19 OU 25. LES OLIGONUCLÉOTIDES SONT UTILISÉS DANS LA DÉTECTION DE L'ÉTAT DE MÉTHYLATION D'UN GÈNE, EN PARTICULIER LE GÈNE MAGE-A3. LES OLIGONUCLÉOTIDES SONT, DE PLUS, UTILISÉS DANS DES PAIRES D'AMORCES, DES KITS ET DES MÉTHODES DE DÉTERMINATION DE L'ÉTAT DE MÉTHYLATION DU GÈNE MAGE-A3 ET DANS LE DIAGNOSTIC DU CANCER, L'ORIENTATION THÉRAPEUTIQUE ET LA SÉLECTION DE SUJETS À DES FINS DE TRAITEMENT. L'AMORCE OU LA SONDE PEUVENT COMPRENDRE UNE STRUCTURE EN BOUCLE OU EN ÉPINGLE À CHEVEUX ET PEUVENT ÊTRE UTILISÉES DANS UNE PCR SPÉCIFIQUE À LA MÉTHYLATION EN TEMPS RÉEL.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96012807P | 2007-09-17 | 2007-09-17 | |
PCT/GB2008/003142 WO2009037438A1 (fr) | 2007-09-17 | 2008-09-17 | Détection améliorée de l'expression de mage-a |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31753B1 true MA31753B1 (fr) | 2010-10-01 |
Family
ID=40239643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32736A MA31753B1 (fr) | 2007-09-17 | 2010-04-01 | Detection amelioree de l'expression de mage-a |
Country Status (18)
Country | Link |
---|---|
US (4) | US8481700B2 (fr) |
EP (2) | EP2201131B8 (fr) |
JP (1) | JP5406839B2 (fr) |
KR (1) | KR20100085917A (fr) |
CN (1) | CN101932723B (fr) |
AU (1) | AU2008300397A1 (fr) |
BR (1) | BRPI0817008A2 (fr) |
CA (2) | CA2699856C (fr) |
CO (1) | CO6260156A2 (fr) |
CR (1) | CR11504A (fr) |
DO (1) | DOP2010000076A (fr) |
EA (1) | EA017879B1 (fr) |
IL (1) | IL204525A0 (fr) |
MA (1) | MA31753B1 (fr) |
MX (1) | MX2010002965A (fr) |
NZ (2) | NZ596545A (fr) |
WO (2) | WO2009037438A1 (fr) |
ZA (1) | ZA201001878B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012037128A2 (fr) * | 2010-09-14 | 2012-03-22 | The University Of North Carolina At Chapel Hill | Procédés et kits pour la détection du mélanome |
WO2012129488A2 (fr) * | 2011-03-23 | 2012-09-27 | Virginia Commonwealth University | Signatures géniques associées au rejet ou à la récurrence du cancer |
CN102251033B (zh) * | 2011-07-05 | 2013-03-20 | 北京大学人民医院 | 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒 |
EP2948566A4 (fr) * | 2013-01-24 | 2016-10-05 | California Inst Of Techn | Caractérisation à base de chromophore et procédés de détection |
ES2859645T3 (es) * | 2013-03-14 | 2021-10-04 | Mayo Found Medical Education & Res | Detección de neoplasia |
GB2550712B (en) | 2015-02-26 | 2021-01-13 | Hitachi High Tech Corp | Method for constructing hairpin-containing nucleic acid molecules for nanopore sequencing |
CN105100961B (zh) * | 2015-07-23 | 2018-03-13 | 华为技术有限公司 | 视频缩略图生成方法及生成装置 |
DE102016005947B3 (de) | 2016-05-16 | 2017-06-08 | Dimo Dietrich | Verfahren zur Abschätzung der Prognose und zur Prädiktion des Ansprechens auf eine Immuntherapie von Patienten mit malignen Erkrankungen |
US11685955B2 (en) | 2016-05-16 | 2023-06-27 | Dimo Dietrich | Method for predicting response of patients with malignant diseases to immunotherapy |
US10294518B2 (en) | 2016-09-16 | 2019-05-21 | Fluxion Biosciences, Inc. | Methods and systems for ultra-sensitive detection of genomic alterations |
WO2018167572A1 (fr) | 2017-03-17 | 2018-09-20 | Mdxhealth Sa | Dosage de séquençage profond épigénétique de mgmt |
US20180271710A1 (en) * | 2017-03-22 | 2018-09-27 | Bragi GmbH | Wireless earpiece for tinnitus therapy |
WO2018237327A1 (fr) | 2017-06-22 | 2018-12-27 | Triact Therapeutics, Inc. | Procédés de traitement d'un glioblastome |
WO2019067991A1 (fr) | 2017-09-29 | 2019-04-04 | Triact Therapeutics, Inc. | Formulations d'iniparib et leurs utilisations |
US11441182B2 (en) * | 2018-08-08 | 2022-09-13 | Virginia Commonwealth University | Multiplexed and recyclable single-molecule sensors for quantitative analysis of nucleic-acid biomarkers |
CN109540856B (zh) * | 2018-11-08 | 2022-01-28 | 南京师范大学 | 一种基于荧光共振能量转移检测不同亚型乳腺癌细胞的试剂 |
CN111551978B (zh) * | 2020-05-08 | 2022-09-27 | 中国辐射防护研究院 | 一种放射性土壤样品采样过程不确定度的评定方法 |
WO2023108145A1 (fr) * | 2021-12-10 | 2023-06-15 | Nuprobe Usa, Inc. | Sondes universelles pour l'amplification et la détection d'acides nucléiques |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4437975A (en) | 1977-07-20 | 1984-03-20 | Mobil Oil Corporation | Manufacture of lube base stock oil |
WO1989001050A1 (fr) | 1987-07-31 | 1989-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Accroissement selectif de sequences de polynucleotides cibles |
AU4829690A (en) | 1988-12-16 | 1990-07-10 | Siska Diagnostics, Inc. | Self-sustained, sequence replication system |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
KR100278157B1 (ko) | 1992-06-25 | 2001-01-15 | 장 스테판느 | 보조약을 함유하는 백신 조성물 |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
EP0772619B2 (fr) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Oligonucleotides immunomodulateurs |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6117635A (en) * | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6291430B1 (en) * | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
CZ298364B6 (cs) * | 1998-02-05 | 2007-09-05 | Smithkline Beecham Biologicals S. A. | Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci |
US6768000B1 (en) | 1998-06-12 | 2004-07-27 | Intergen Company | Multi-fluorescent hairpin energy transfer oligonucleotides |
ATE315405T1 (de) | 1998-08-10 | 2006-02-15 | Antigenics Inc | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung |
US6667037B1 (en) | 1998-10-09 | 2003-12-23 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof |
CZ303515B6 (cs) | 1999-04-19 | 2012-11-07 | Smithkline Beecham Biologicals S. A. | Adjuvantní prostredek |
US6331393B1 (en) * | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
US20040170977A1 (en) * | 2000-03-31 | 2004-09-02 | Peter Laird | Epigenetic sequences for esophageal adenocarcinoma |
AU2002312764A1 (en) | 2001-03-15 | 2002-10-21 | Schrenzel, Jacques | Detection of methicillin-resistant staphylococcus aureus (mrsa) |
WO2003046142A2 (fr) | 2001-11-26 | 2003-06-05 | Avigen, Inc. | Procedes de production de populations de virions de virus recombine adeno-associe |
HUP0500539A2 (en) | 2002-02-04 | 2006-09-28 | Corixa Corp | New immunoeffector 2-deoxi-2-amino-3-d glucopyranose derivatives |
DE10215770A1 (de) * | 2002-04-10 | 2003-10-30 | Michael Giesing | Verfahren zum Nachweis methylierter und/oder nichtmethylierter Cytosine in Nukleinsäuren, dessen Verwendung sowie entsprechende Analysekits |
WO2004067726A2 (fr) | 2003-01-29 | 2004-08-12 | Keck Graduate Institute | Reactions isothermes pour amplification d'oligonucleotides |
WO2004087957A2 (fr) * | 2003-04-03 | 2004-10-14 | Oncomethylome Sciences S.A. | Genes hypermethyles et cancer du col de l'uterus |
US7881873B2 (en) * | 2003-04-29 | 2011-02-01 | The Jackson Laboratory | Systems and methods for statistical genomic DNA based analysis and evaluation |
DE10329240A1 (de) | 2003-06-24 | 2005-01-20 | Epigenomics Ag | Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie |
DE10338308B4 (de) * | 2003-08-15 | 2006-10-19 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungen in DNA |
EP1692264A2 (fr) | 2003-10-28 | 2006-08-23 | The Johns Hopkins University | Pcr quantitative multiplex specifique de la methylation |
US20050130170A1 (en) * | 2003-12-16 | 2005-06-16 | Jeanne Harvey | Identification and verification of methylation marker sequences |
DK1659186T3 (da) * | 2004-10-11 | 2008-09-22 | Epigenomics Ag | Fremgangsmåde til kontaminationsbeskyttelse i DNA-amplifikationssystemer til methyleringsanalyse opnået ved en modificeret forbehandling af nukleinsyrer |
US20070059753A1 (en) * | 2005-09-15 | 2007-03-15 | Tatiana Vener | Detecting gene methylation |
GB0612342D0 (en) * | 2006-06-21 | 2006-08-02 | Glaxosmithkline Biolog Sa | Method |
GB0700374D0 (en) | 2007-01-09 | 2007-02-14 | Oncomethylome Sciences S A | NDRG family methylation markers |
US8911937B2 (en) * | 2007-07-19 | 2014-12-16 | Brainreader Aps | Method for detecting methylation status by using methylation-independent primers |
-
2008
- 2008-09-17 NZ NZ596545A patent/NZ596545A/xx not_active IP Right Cessation
- 2008-09-17 MX MX2010002965A patent/MX2010002965A/es not_active Application Discontinuation
- 2008-09-17 WO PCT/GB2008/003142 patent/WO2009037438A1/fr active Application Filing
- 2008-09-17 KR KR1020107008201A patent/KR20100085917A/ko active IP Right Grant
- 2008-09-17 NZ NZ583796A patent/NZ583796A/en not_active IP Right Cessation
- 2008-09-17 WO PCT/GB2008/003145 patent/WO2009037441A1/fr active Application Filing
- 2008-09-17 CA CA2699856A patent/CA2699856C/fr active Active
- 2008-09-17 AU AU2008300397A patent/AU2008300397A1/en not_active Abandoned
- 2008-09-17 CN CN200880117371.0A patent/CN101932723B/zh not_active Expired - Fee Related
- 2008-09-17 US US12/678,702 patent/US8481700B2/en not_active Expired - Fee Related
- 2008-09-17 US US12/678,706 patent/US9050280B2/en active Active
- 2008-09-17 EP EP08806301.1A patent/EP2201131B8/fr active Active
- 2008-09-17 CA CA2699853A patent/CA2699853A1/fr not_active Abandoned
- 2008-09-17 JP JP2010524578A patent/JP5406839B2/ja not_active Expired - Fee Related
- 2008-09-17 EP EP08806298A patent/EP2198045A1/fr not_active Withdrawn
- 2008-09-17 BR BRPI0817008A patent/BRPI0817008A2/pt not_active IP Right Cessation
- 2008-09-17 EA EA201000334A patent/EA017879B1/ru not_active IP Right Cessation
-
2010
- 2010-03-11 DO DO2010000076A patent/DOP2010000076A/es unknown
- 2010-03-16 IL IL204525A patent/IL204525A0/en unknown
- 2010-03-16 ZA ZA2010/01878A patent/ZA201001878B/en unknown
- 2010-03-19 CO CO10033047A patent/CO6260156A2/es not_active Application Discontinuation
- 2010-04-01 MA MA32736A patent/MA31753B1/fr unknown
- 2010-06-16 CR CR11504A patent/CR11504A/es not_active Application Discontinuation
-
2013
- 2013-06-13 US US13/917,108 patent/US20130302363A1/en not_active Abandoned
-
2015
- 2015-06-08 US US14/733,152 patent/US10053724B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31753B1 (fr) | Detection amelioree de l'expression de mage-a | |
Gaudin et al. | Hybrid capture-based next generation sequencing and its application to human infectious diseases | |
Miotke et al. | High sensitivity detection and quantitation of DNA copy number and single nucleotide variants with single color droplet digital PCR | |
Valencia et al. | Comprehensive mutation analysis for congenital muscular dystrophy: a clinical PCR-based enrichment and next-generation sequencing panel | |
Henne et al. | Analysis of structure and composition of bacterial core communities in mature drinking water biofilms and bulk water of a citywide network in Germany | |
Heinen | Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer | |
US8239136B2 (en) | Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject | |
JP6722659B2 (ja) | 結腸直腸癌のためのメチル化マーカー | |
Soares Bispo Santos Silva et al. | Evaluation of DNA methylation markers and their potential to predict human aging | |
Cervena et al. | Methylation-based therapies for colorectal cancer | |
MX2007008984A (es) | Marcadores de cancer y metodos de deteccion. | |
Nazari-Vanani et al. | Electrochemical biosensing of 16s rRNA gene sequence of Enterococcus faecalis | |
Park et al. | Traveller-associated high-level ciprofloxacin-resistant Salmonella enterica Serovar Kentucky in the Republic of Korea | |
JP2017511138A5 (fr) | ||
Biran et al. | Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques | |
JP2016510982A5 (fr) | ||
CN103757028A (zh) | Osbpl2突变型基因、其鉴定方法和检测试剂盒 | |
WO2003026488A3 (fr) | Diagnostic et traitement d'une maladie vasculaire | |
RU2010149949A (ru) | Тест-система для определения мутаций в генах фумарилацетоацетат гидролазы и альфа-1-антитрипсина человека | |
RU2440415C1 (ru) | Набор синтетических олигонуклеотидов для определения нуклеотидной последовательности кодирующей части гена brca1 и выявления мутаций, ассоциированных с наследственными формами рака молочной железы | |
AR099950A1 (es) | Determinación de polimorfismos de un solo nucleótido de utilidad para la predicción de la respuesta a la rasagilina | |
US20230132088A1 (en) | Detection of gene polymorphisms | |
Prescott et al. | From linkage maps to quantitative trait loci: the history and science of the Utah genetic reference project | |
Goire et al. | The influence of target population on nonculture-based detection of markers of Neisseria gonorrhoeae antimicrobial resistance | |
US10550432B2 (en) | Method for predicting risk of ankylosing spondylitis using DNA copy number variants |